Pembrolizumab versus Ipilimumab in Advanced Melanoma

In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival.

Website: http://www.arjonline.org/medicine-and-health-care/american-research-journal-of-gynecology/